Novo Nordisk and UBE Industries have announced that Novo Nordisk has obtained an exclusive worldwide licence to UBE’s preclinical asset UD-014, a selective Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) inhibitor
Nordic Life Science
NLS Pharma News
Pharma
LIDDS licensee Jiangxi Puheng Pharma has after reviewing the preliminary results in LPC-004 decided to move ahead and has initiated discussions with Chinese medical authority, CFDA. The phase III study
Klaria Pharma Holding has acquired Uppsalagruppen Medical AB and the patent that protects Klaria’s drug delivery technology, it has also merged with Karessa Pharma Holding to create a focused drug
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm.
The company has launched Recipharm Analytical Solutions, a stand-alone service to support pharmaceutical companies with their Quality Control (QC) and analytical requirements. Recipharm Analytical Solutions, which launches at CPhI Worldwide,
Medivir has announced that the first patient has been enrolled in a phase I study to investigate the safety and tolerability of a combination treatment of birinapant and radiation therapy
Clinical trials
Follicum has announced that the company has signed a collaboration agreement with proDERM for conducting the new clinical trial with
LIDDS licensee Jiangxi Puheng Pharma has after reviewing the preliminary results in LPC-004 decided to move ahead and has initiated
Vaccibody has announced strong preliminary data from the ongoing VB N-01 phase I/IIa clinical trial of the VB10.NEO neoantigen cancer
LIDDS has received approval from authorities in Lithuania to conduct its Phase I study, NZ-DTX-001. The aim of the phase
Gedea Biotech reports that all 24 patients have been treated with its lead product, pHyph, a vaginal tablet for topical
Medivir has announced that the first patient has been enrolled in a phase I study to investigate the safety and
The company has announced results from a preclinical study examining ilixadencel, an off-the-shelf, cell-based immune primer, tested in combination with
Data from a voluntary open label extension (OLE) study indicates longer PSA effect with Liproca Depot in prostate cancer patients
The company has initiated the first-in-human trial of MVA-BN WEV, a prophylactic vaccine candidate against the equine encephalitis virus –
The first cohort of 40 adults was enrolled in the company’s Phase I study in Zambia. The study is part
During its first year the bioprocess pilot-scale facility in Uppsala has hosted fifteen national and international projects and more than
The company has announced that the last patient has been included in the OP-106 HORIZON phase 2 clinical study evaluating
The company has reported the first results from their Proof of Concept STAR study in subjects with prediabetes or newly
The Oslo University Hospital, has been included as a site in the ongoing ONCOS-102 trial in anti-PD1 refractory, advanced melanoma.
The company has announced preliminary data from the LPC-004 study that aimed to determine the tolerability of Liproca Depot and
The company has announced the complete analysis of the data from the Phase II MERECA clinical trial. The study evaluated
Profiles in Pharma
Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new
She joined LEO Pharma by chance, more than 27 years ago, but she remained there, for the true focus on
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments